House Bill 6417
116th Congress(2019-2020)
Protecting Cures Act of 2020
Introduced
Introduced in House on Mar 31, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6417
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Jan Schakowsky
grade
Illinois
California
California
California
Colorado
Connecticut
District of Columbia
Florida
Florida
Indiana
Maryland
Maryland
Massachusetts
Massachusetts
New Jersey
New Mexico
New York
Rhode Island
Tennessee
Texas
Vermont
Washington
Wisconsin
No House votes have been held for this bill.
Summary
Protecting Cures Act of 2020
This bill prohibits the Department of Health and Human Services from withholding funding, because of ethical considerations, for research activities that use human fetal tissue, provided that the research activities have been recommended for approval by an institutional review board and otherwise comply with existing laws concerning human fetal tissue. The bill also establishes that this research is not unethical by deeming the 1988 report of the Human Fetal Tissue Transplantation Research Panel as meeting relevant statutory requirements with respect to approving the ethical status of such research.
March 31, 2020
03/31/2020
Referred to the House Committee on Energy and Commerce.
03/31/2020
Introduced in House
Public Record
Record Updated
Feb 8, 2022 11:17:24 PM